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HIGHLIGHTS  
 
 Cannabis use is common among patients in the early stage of psychosis 
 Cannabis-using early psychosis patients are more frequently readmitted to hospital 
 Cannabis-using male and Black patients are particularly at risk of readmission  
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Abstract 
 
Cannabis is the most commonly used illicit drug in psychosis patients and has been 
identified as a risk factor for relapse and subsequent hospital readmission, having substantial 
economic implications. To clarify the contribution of cannabis consumption to hospital 
readmission, a consecutive inpatient cohort of 161 early psychosis patients was included into 
the study. Data on cannabis use at admission and number of hospital readmissions and length 
of stay (LOS, number of inpatient days) in a 6-year follow-up was extracted from clinical 
notes. 62.4% of the patients had lifetime cannabis use. Their admission lasted on average 
54.3±75 days and over the following 6 years patients had 2.2±2.8 hospital readmissions, for a 
total of 197.4±331.5 days. Cannabis use significantly predicted the number of hospital 
readmissions and LOS in the following 6 years, the latter remaining significant after adjusting 
for use of other substance. Cannabis-using patients of male gender and Black ethnicity had a 
longer LOS at follow-up compared to female patients and other ethnic groups, respectively. 
Having a history of cannabis use when admitted to an early intervention inpatient unit for 
psychosis is associated with a higher number of subsequent hospital readmissions and a 
longer LOS, especially in male and Black patients.  
 
Keywords: Schizophrenia, Substance use, Relapse, Male gender, Black ethnicity 
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1. Introduction 
 
In recent years, more attention has been paid to the public health impact of cannabis 
use, especially by young adults (Hall and Lynskey, 2016) with evidence of a growing 
prevalence of regular cannabis use worldwide, with approximately 200 million users 
(National Academies of Sciences, 2017). Convergent and replicated findings indicate that 
cannabis use can induce psychotic symptoms (Henquet et al., 2005; Skinner et al., 2011; van 
Gastel et al., 2012) and increase the risk of developing a psychotic disorder (Colizzi and 
Murray, 2018; Moore et al., 2007; Radhakrishnan et al., 2014; Sami et al., 2017), especially 
in young and vulnerable individuals with a history of heavy use (Colizzi et al., 2015a; Colizzi 
et al., 2015b). This is in line with experimental evidence that acute administration of delta-9-
tetrahydrocannabinol (∆9-THC) as well as cannabinoid agonists, including 
phytocannabinoids and synthetic cannabinoids, induce transient psychosis-like symptoms and 
cognitive impairments in individuals at clinical high-risk to develop a psychotic disorder 
(Vadhan et al., 2017) as well as healthy individuals (Bhattacharyya et al., 2009; D'Souza et 
al., 2004; Sherif et al., 2016). Recent evidence indicates that almost one in two patients with 
cannabis-induced psychosis develops schizophrenia or bipolar disorder, being the highest rate 
of conversion to a severe psychiatric disorder among patients with a substance-induced 
psychosis (Starzer et al., 2018). However, whether the association between cannabis and 
psychosis is causal in nature is still debated (Ksir and Hart, 2016a, b; Schoeler et al., 2016b). 
Cannabis is also the most commonly used illicit drug in patients with established psychosis 
(Moore et al., 2012) and its use is especially high in young people presenting with their first 
episode of psychosis (Patel et al., 2016). Research evidence suggests that continued cannabis 
use after the onset of psychosis predicts poor disease outcome (Linszen et al., 1994), as also 
confirmed by a recent meta-analysis (Schoeler et al., 2016a). More specifically, cannabis use 
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has been shown to exacerbate psychotic symptoms (Ouellet-Plamondon et al., 2017; Schoeler 
et al., 2016a; Seddon et al., 2016), increase risk of non-remission (Colizzi et al., 2016) and 
cause relapse (Patel et al., 2016; Schoeler et al., 2016c) in a dose-dependent manner 
(Schoeler et al., 2016d). Moreover, cannabis represents a risk factor for both poor medication 
adherence (Colizzi et al., 2016; Foglia et al., 2017; Schoeler et al., 2017a),  antipsychotic 
treatment-failure (Patel et al., 2016; Wilson and Bhattacharyya, 2016) and dropout from 
treatment (Miller et al., 2009) and the association between cannabis use and poor outcome in 
psychosis may be mediated by its effects on medication non-adherence (Colizzi et al., 2016; 
Schoeler et al., 2017b) and treatment failure (Patel et al., 2016). Cannabis-associated 
psychosis relapse may have substantial economic implications in light of the potential 
subsequent need for hospital care (Knapp et al., 2009). Within the first 2 years after the onset 
of either affective or non-affective psychosis up to 50% of patients experience a relapse 
which results in hospital readmission, with the risk exceeding 80% by the 8
th
 year of illness 
(Alvarez-Jimenez et al., 2012).  
Several studies have investigated the effect of cannabis use on risk of relapse and 
hospitalization in incident cohorts of psychosis patients (Schoeler et al., 2016a). On the other 
hand, only limited research has specifically evaluated the effects of cannabis use on psychosis 
outcome in inpatient cohorts (Foti et al., 2010; Rylander et al., 2017; San et al., 2013). 
Specifically, one study assessed relapse rates during a 1-year follow-up in an inpatient cohort 
of schizophrenia spectrum disorder patients with long and varying duration of illness (ranging 
from ≤ 5 years to > 20 years), indicating that cannabis consumption was a risk factor for 
relapse (San et al., 2013). Another study followed up for 1 month patients admitted to 
hospital with psychotic symptoms, finding that, compared to patients testing negative for the 
presence of the active metabolite of cannabis 11-nor-9-carboxy-Δ9-tetrahydrocannabinol 
(THC-COOH), those acutely intoxicated with cannabis required a shorter inpatient 
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psychiatric hospitalization. However, the groups did not differ in terms of readmission rates, 
presentation to psychiatric emergency services, or symptom severity at follow-up (Rylander 
et al., 2017). One more study followed up schizophrenia spectrum disorder patients for 10 
years after their first admission, suggesting an adverse course of psychotic symptoms in 
cannabis-using patients (Foti et al., 2010). Collectively, the interpretation of these findings is 
challenging in light of methodological heterogeneity between the studies in terms of outcome 
variable (relapse, hospital readmission, or symptom course), follow-up (from 1 month to 10 
years), and illness stage (first presentation, chronic psychosis) or severity (acute drug-induced 
psychosis, established psychosis). Also, these studies investigated the contributing impact of 
other illicit drugs on psychosis outcome. In particular, Foti et al. indicated that cannabis use is 
associated with an adverse course of psychotic symptoms even after controlling for stimulant 
and cocaine use (Foti et al., 2010). Rylander et al. found that patients testing negative for 
cannabis and patients with a urine toxicology screen positive for cannabis do not differ in 
terms of positivity for other stimulants, including cocaine, amphetamine, and opioids 
(Rylander et al., 2017).  Interestingly, San et al. indicated that consumption of cocaine, and 
not heroin, is a risk factor for psychosis relapse independent of cannabis use (San et al., 
2013).  Conversely, these studies didn’t take into account the potential confounding effect of 
other common substances such as alcohol (Foti et al., 2010; San et al., 2013) and/ or tobacco 
(Foti et al., 2010; Rylander et al., 2017; San et al., 2013). Alcohol and tobacco have been 
identified as a significant problem in people with schizophrenia (Bouza et al., 2010) and 
meta-analytic evidence indicates that tobacco use represented a risk factor for psychosis 
(Gurillo et al., 2015). Thus, the association between alcohol and tobacco use on one hand and 
psychosis outcome on the other merits further examination. 
Therefore, in a consecutive inpatient cohort of patients admitted for psychosis to a 
specialist Early Intervention inpatient Unit within a 1-year period, we obtained information 
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from clinical records on current admission, past medical history, and cannabis as well as 
other substance use. Information on clinical outcome in terms of subsequent inpatient care, 
such as the number of readmissions and days spent in hospital over a 6-year follow-up period 
was also extracted from electronic clinical notes. This study design allowed us to mitigate the 
potential confounding effects of short follow-up (Baeza et al., 2009), high attrition rate 
(Potthoff, 2017), and illness stage or severity (Schoeler et al., 2016a). Therefore, the strength 
of our study was the ability to examine the following hypothesis: cannabis use in patients 
with early psychotic disorder, which was not a result of merely acute cannabis intoxication, 
would be associated with higher hospital readmission rates over a longer-term follow-up. As 
gender and ethnicity have been shown to be the most consistent unique predictors of lifetime 
substance use disorders in patients in the early stage of their psychosis (Brunette et al., 2017), 
exploratory analyses assessed the potential role of these variables in the association between 
cannabis use and hospital readmission rates. 
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2. Methods 
 
  
 
2.1. Study design and sample 
 
This chart review study was conducted at the Early Intervention inpatient Unit of the South 
London and Maudsley NHS Foundation Trust (SLaM), an inpatient facility specifically 
devoted to the care of young people aged between 18 and 35 experiencing psychosis for the 
first time, as part of a clinical audit. All consecutive admissions to the inpatient service over 
the 2010 calendar year were included into the study. Patients with a known or suspected 
acute substance intoxication as well as organic cause for psychosis were excluded. This 
study incorporates a longitudinal design. In fact, although data was collected retrospectively, 
this information was extracted from prospectively recorded routine clinical information over 
the follow-up period following the index admission in 2010. For all patients, we were able to 
extract data over the 6-year follow-up period after their admission to the inpatient unit, 
obtaining satisfactory data in terms of number of readmissions and days spent in hospital. 
The design of the electronic system didn’t allow a systematic assessment of patients’ 
cognitive function or symptom severity. 
The authors assert that the work described here has been carried out in accordance 
with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for 
experiments involving humans as well as the Uniform Requirements for manuscripts 
submitted to biomedical journals. 
 
2.2. Case-tracing procedure 
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All relevant information about the study participants was extracted from the clinical 
records held on the South London and Maudsley Mental Health NHS Foundation Trust 
(SLaM) electronic Patient Journey System (ePJS). The SLaM ePJS comprises fields for 
demographic information as well as fields from case notes and correspondence where history, 
mental state examination, diagnostic formulation and management plan are primarily 
recorded. All of the following measures were extracted by a qualified psychiatrist and/ or 
clinical researcher retrospectively from the electronic mental health records system.  
 
2.3. Data extracted at admission 
 
Socio-demographic information including gender, self-reported ethnicity, and age at 
the time of the admission was extracted from the clinical records. Duration of current 
admission and information on potential previous contacts with psychiatric services were also 
recorded. Finally, information on lifetime use of cannabis and other common substances, 
including tobacco, alcohol, and stimulants (such as amphetamine, cocaine, etc.) was extracted 
from fields in the ePJS including clinical assessments, reviews and correspondence between 
healthcare professionals.  
 
2.4. Data extracted at follow-up 
 
The six-year follow-up period was considered from the date of inpatient admission in 
2010 to the SLaM Early Intervention inpatient Unit for psychosis until the 31
st
 of December 
2016. Outcome variables of interest were the number of readmissions and total number of 
days spent in hospital within the follow-up period.  
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2.5. Data Analysis 
 
Negative binomial regressions were used to test for an effect of baseline cannabis use 
(yes/ no) as recorded at the index hospitalization on number of hospital readmissions and 
length of stay (LOS, number of inpatient days) in the following 6 years, controlling for the 
confounding effects of socio-demographic characteristics (age, gender, ethnicity), clinical 
characteristics at baseline (duration of current admission, number of previous admissions to 
inpatient mental health services) and other substance use (tobacco, alcohol, stimulants). 
Negative binomial regressions were also used to explore the interaction between cannabis use 
and gender as well as cannabis use and ethnicity on number of hospital readmissions and 
days spent in hospital in the following 6 years, controlling for the same confounders.  
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3. Results 
 
3.1. Sociodemographic characteristics 
 
There were 161 new admissions to the Early Intervention Unit in 2010. Out of this 
cohort, 13 patients (8.1 %) had a second admission and 1 (0.6%) patient had a third 
admission within the same calendar year. Also, 61% of the patients were male and their 
average age at the time of admission was 29.8 years (± SD, ± 9.5 years). 28% of the patients 
were White, 50.7% Black African/ Caribbean, 13.3% Asian, and 8% had a mixed self-
reported ethnicity.  
 
3.2. Clinical measures   
 
 The current admission lasted on average 54.3 ± 75 days. Patients had 1.7 ± 2.7 (Mean 
±SD) previous inpatient admissions(s). Over the following 6 years patients had 2.2 ± 2.8 
hospital readmissions, for a total of 197.4 ± 331.5 days (length of stay, LOS). 
 
3.3. Cannabis and other substance use 
 
Information on cannabis use was available for 141 early psychosis patients. At 
admission, 62.4% had a lifetime history of cannabis use as recorded in the case notes, which 
was considered clinically significant. Lifetime use of other substances as recorded in case 
notes was also frequent, with 61.2% tobacco users, 64.5% alcohol users, and 38.5% stimulant 
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users. Sociodemographic characteristics, clinical measures, and other substance use in early 
psychosis patients with and without a history of cannabis use are reported in Table 1.   
 
3.4. Effect of cannabis use on hospital readmission rates 
 
A negative binomial regression to test for an effect of cannabis use on the number of 
hospital readmissions over the following 6 years, adjusting for sociodemographic (age, 
gender, and ethnicity) and other clinical characteristics at baseline (duration of current 
admission, number of previous contact(s) with inpatient psychiatric services), suggested that 
cannabis use significantly predicted the number of hospital readmissions over the following 6 
years (B = 0.56, SE = 0.26, Chi square = 4.74, p = 0.029; Table 2A).  
A further negative binomial regression, adjusting also for use of psychoactive 
substances other than cannabis (tobacco, alcohol, and stimulants) in addition to 
sociodemographic and other clinical characteristics at baseline, failed to reach significance 
for an effect of cannabis use on the number of hospital readmissions over the following 6 
years (B = 1.18, SE = 0.66, Chi square = 3.23, p = 0.072; Table 2B). This was carried in a 
smaller subset (N = 71) of the larger cohort for whom data on use of psychoactive substances 
other than cannabis (tobacco, alcohol, and stimulants) was recorded in clinical notes. 
A second negative binomial regression to test for an effect of cannabis use on length 
of stay (LOS, number of days spent in hospital) over the following 6 years, adjusting for 
sociodemographic and other clinical characteristics at baseline, suggested that cannabis use 
significantly predicted LOS over the following 6 years (B = 0.77, SE = 0.23, Chi square = 
10.97, p = 0.001; Table 3A). 
A further negative binomial regression, adjusting also for use of psychoactive 
substances other than cannabis in addition to sociodemographic and other clinical 
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characteristics at baseline, demonstrated an effect of cannabis use on LOS over the following 
6 years (B = 1.41, SE = 0.70, Chi square = 4.04, p = 0.044; Table 3B). This was carried in the 
smaller subset (N = 71) of the larger cohort for whom data on use of psychoactive substances 
other than cannabis was recorded in clinical notes. 
 
3.5. Exploratory analyses 
 
A negative binomial regression adjusting for all the modeled potential confounders 
(sociodemographic and other clinical characteristics, and substance use) failed to show a 
significant interaction between cannabis use and gender on the number of hospital 
readmissions over the following 6 years. However, a further negative binomial regression 
adjusting for all the modeled potential confounders (sociodemographic and other clinical 
characteristics, and substance use) showed a significant interaction between cannabis use and 
gender on LOS over the following 6 years. Compared to female cannabis-naïve patients, 
cannabis use predicted LOS over the following 6 years among male (B = 1.49, SE = 0.72, Chi 
square = 4.28, p = 0.038; Table 4) but not female patients (p = 0.34; Table 4). 
A second negative binomial regression adjusting for all the modeled potential 
confounders (sociodemographic and other clinical characteristics, and substance use) showed 
a significant interaction between lifetime cannabis use and ethnicity on the number of 
hospital readmissions over the following 6 years. Compared to White cannabis-naïve 
patients, cannabis use was significantly associated with the number of hospital readmissions 
over the following 6 years among patients of Black African/ Caribbean (B = 1.54, SE = 0.79, 
Chi square = 3.86, p = 0.049; Table 5A), but not White (p = 0.90; Table 5A) or Asian 
ethnicity (p = 0.82; Table 5A). 
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A further negative binomial regression adjusting for all the modeled potential 
confounders (sociodemographic and other clinical characteristics, and substance use) showed 
a significant interaction between cannabis use and ethnicity on LOS over the following 6 
years. Compared to White cannabis-naïve patients, cannabis use predicted LOS over the 
following 6 years among patients of Black African/ Caribbean (B = 2.39, SE = 0.90, Chi 
square = 7.10, p = 0.008; Table 5B), but not White (p = 0.53; Table 5B) or Asian ethnicity (p 
= 0.29; Table 5B). 
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4. Discussion 
 
To our knowledge, this is the first study to systematically examine the association of 
cannabis use and hospital outcomes over a longer-term in an inpatient cohort of early 
psychosis patients. The results indicated that having a history of cannabis use when admitted 
to hospital in the early stage of psychosis predict a higher number of hospital readmissions as 
well as a longer length of stay (LOS, number of days spent in hospital) in the subsequent 6 
years. The association between cannabis use and LOS remained significant when controlling 
for the confounding effects of use of other common substances, such as alcohol, tobacco, and 
stimulants. Finally, the negative effect of cannabis use in terms of longer hospital 
readmissions was greater in cannabis-using patients of male gender and Black ethnicity 
compared to the female gender and other ethnic groups, respectively. 
The mean age of the cannabis-using group was consistent with previous studies 
investigating the effect of cannabis use on psychosis onset in patients presenting with their 
first episode of psychosis to the adult in-patient units of the South London and Maudsley 
NHS Foundation Mental Health Trust (Di Forti et al., 2014). Our inpatient cohort was 
characterized by high rates of cannabis and other substance use, in line with previous surveys 
of drug use in psychosis (Moore et al., 2012). However, the prevalence of substance use we 
found was higher compared to that of other studies investigating substance use in early 
psychosis because we included any kind of use and not only categorically defined substance 
use disorders (Addington and Addington, 2007; Myles et al., 2012; Van Mastrigt et al., 
2004). Substance use and other mental disorders frequently co-occur, complicating diagnosis 
because many symptoms, such as insomnia, can fulfill criteria for intoxication, withdrawal 
syndrome, or other mental disorders (Hasin et al., 2013). Studies indicated that substance use 
disorders represent a dimensional condition with no natural threshold, with a binary 
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diagnostic decision potentially resulting in a marked perturbation in prevalence (Russo et al., 
2014). Also, defining patients on the basis of a comorbid substance use disorder would have 
affected the generalizability of the results, limiting their application only to early psychosis 
patients at the extreme hand side of substance use comorbidity.  
Our study evaluated the impact of cannabis use on hospital readmission rates 
controlling for a number of clinical and sociodemographic variables. In the 1990s, 
methodologically robust studies started to suggest that several features may influence 
readmissions rates among psychiatric patients. The number of previous admissions appeared 
to be the best explanatory clinical factor for subsequent admissions (Colenda and Hamer, 
1989; Wan and Ozcan, 1991). Also, among sociodemographic exploratory variables, patients 
of male gender were reported at higher future risk of single and multiple readmissions and of 
subsequently remaining longer in hospital (Kastrup, 1987). Other studies have consistently 
shown that younger age (Lewis and Joyce, 1990; Zilber et al., 1990) and ethnicity (Bhugra et 
al., 1997) are associated with poor outcome in those with psychosis. Clinical and 
sociodemographic exploratory variables for higher risk of readmission found in the present 
study (Table 2 and 3) are entirely consistent with previous work. Our findings indicated that 
cannabis use affect hospital readmissions rates and LOS even beyond the early years of 
illness even after controlling for these potential confounders, and has demonstrated this 
association in an inpatient cohort. Our results also extended previous evidence (Bhugra et al., 
1997; Kastrup, 1987), indicating that the risk of hospital readmission due to cannabis use is 
significantly higher in male and Black patients compared to female patients and patients of 
other ethnicity.  
Stimulant and alcohol use appeared to have an effect on the LOS but not on the 
number of hospital admissions in the subsequent 6 years. In particular, stimulant use was 
associated with longer LOS, complementing previous evidence that stimulant use, especially 
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cocaine, may increase the risk of psychosis relapse independent of cannabis use (San et al., 
2013). Conversely, alcohol use was associated with a shorter LOS. Research evidence has 
suggested a negative association between frequency of cannabis use and hazardous alcohol 
use (Berge et al., 2014). However, while the current study controlled for the confounding 
effect of other substance use in the association between cannabis use and hospital 
readmission rates, it was not designed to investigate the effect of hazardous alcohol use on 
risk of being readmitted to hospital. Thus, these findings will not be further discussed. 
Several explanations may account for the higher risk of being readmitted to hospital in 
cannabis-using early psychosis patients. A review of clinical studies suggested that cannabis 
use may impact negatively on a number of psychosocial factors, including employment rates 
and quality of life (Zammit et al., 2008). Moreover, substance use has been shown to affect 
physical health (Colton and Manderscheid, 2006; Crump et al., 2013), with approximately 
60% of premature deaths in schizophrenia patients being due to medical conditions caused by 
modifiable risk factors such as smoking, alcohol consumption, and drug use (Hartz et al., 
2014). Also, neurobiological mechanisms may be involved in light of evidence that cannabis-
using and non-using patients with psychosis may differ on a number of biological 
characteristics (reviewed here (Sami and Bhattacharyya, 2018)). Chronic cannabis use has 
also been suggested to lead to low striatal dopamine synthesis and release, which in turn may 
drive craving for further drug use (Bloomfield et al., 2014; Murray et al., 2014). 
Antipsychotic medications block dopamine and therefore may compound this low striatal 
dopamine leading to greater craving and dropout from treatment (Miller et al., 2009). 
Cannabis use is also a well-known risk factor for poor medication adherence (Colizzi et al., 
2016; Foglia et al., 2017; Schoeler et al., 2017a). Furthermore, experimental studies have 
shown that the main psychoactive ingredient in cannabis can induce psychotic symptoms in 
healthy individuals (Bhattacharyya et al., 2015; Bhattacharyya et al., 2012; Bhattacharyya et 
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al., 2009; D'Souza et al., 2004) and exacerbate their severity in those with pre-existing 
psychosis (D'Souza et al., 2005), suggesting that comorbid cannabis use may increase the risk 
of readmission simply by making patients with psychosis more unwell. All these factors may 
globally affect the mental health of patients with psychosis, increasing their risk of being 
readmitted to hospital. 
In summary, this study adds to the larger body of evidence indicating a detrimental 
effect of cannabis use on psychosis outcome. In particular, cannabis use increased the risk of 
being readmitted to hospital in the 6 years after discharge from an inpatient early psychosis 
unit, especially in patients of male gender and Black ethnicity. On the available 
epidemiological evidence (Schoeler et al., 2016a), despite being one of the most potentially 
preventable risk factors of psychosis, cannabis use represents a great obstacle to the effective 
treatment of the disorder. The establishment of training and education programs in psychosis 
with comorbid cannabis use for health professionals, care providers, as well as for the general 
population may increase knowledge of cannabis use as a risk factor for relapse and hospital 
readmission in psychosis and help to improve patients’ outcome in the long-term. 
Encouraging future research oriented to early intervention in psychosis with comorbid 
cannabis use can speed the process of identifying evidence-based best practices, support the 
creation of public policies, and reduce subsequent burden on services, being eventually 
beneficial to society.  
The main strengths of the present study were its in-patient cohort design, the 
prospective long-term follow-up, and the fact that it controlled for potential confounding 
effects of the most common sociodemographic and clinical characteristics, and other 
substance use. Also, having patient clinical information stored electronically increased 
availability of data and helped reducing loss to follow-up. However, the possibility of 
disengagement from the clinical team after the hospitalization, transfer to other mental health 
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services within the UK, or moving abroad cannot be completely ruled out. Moreover, all 
information was recorded by trained assessors over multiple assessments during the 6-year 
follow-up, ensuring the reliability of data collected. However, as the electronic system is not 
primarily designed for research purposes, clinical notes may lack of standardization and 
information that is not important to clinical care may be missing. For instance, information on 
frequency and type of cannabis use was not systematically reported, precluding the 
evaluation of the effect of different patterns of cannabis use on hospital readmission. Also, 
the lack of systematic assessment of alcohol, tobacco, and stimulant use across patients 
limited the statistical power of analyses conducted adjusting for the potential confounding 
effect of other commonly used substances. Nevertheless, the substantial overlap in terms of 
results between analyses conducted with and without other substances use as a confounder, 
excludes that the present findings may be systematically affected by a potential selection bias 
in data availability. Furthermore, not having information whether cannabis use continued 
over the follow-up period represented another limitation of this study.  
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Table 1. Sociodemographic characteristics, clinical measures, and other substance use 
in psychosis patients with and without a lifetime history of cannabis use 
 
       Total group Cannabis users Cannabis-naïve  
   
  
  
   N (%) N (%) N (%) 
   141 (100) 88 (62.4) 53 (37.6) 
   
  
  
 Gender 
  
  
 Male 87 (62.1) 63 (71.6) 24 (46.2) 
 Female 53 (37.9) 25 (28.4) 28 (53.8) 
 Missing 1 
 
  
   
  
  
 Ethnicity 
  
  
 Asian 15 (11.3) 8 (9.4) 7 (14.6) 
 Black African/ Caribbean 68 (51.1) 43 (50.6) 25 (52.1) 
 Mixed 12 (9) 8 (9.4) 4 (8.3) 
 White 38 (28.6) 26 (30.6) 12 (25) 
 Missing 8 
 
  
   
  
  
 Alcohol use 
  
  
 Yes 74 (63.2) 58 (84.1) 16 (33.3) 
 No 43 (36.8) 11 (15.9) 32 (66.7) 
 Missing 24 
 
  
   
  
  
 Tobacco use 
  
  
 Yes 60 (60) 53 (96.4) 7 (15.6) 
 No 40 (40) 2 (3.6) 38 (84.4) 
 Missing 41 
 
  
   
  
  
 Stimulant use 
  
  
 Yes 41 (36.3) 40 (65.6) 1 (1.9) 
 No 72 (63.7) 21 (34.4) 51 (98.1) 
 Missing 28 
 
  
  
Substance use  
At least one other substance a 
No other substance 
Missing 
93 (77) 
28 (23) 
20 
74 (97) 
2 (3) 
 
19 (42) 
26 (58) 
  
 
  M (SD) 
 
M (SD) M (SD) 
   
  
  
 Age (years) 29.21 (9.29) 28.52 (9.25) 30.36 (9.34) 
 [range] 
  
[18-69] 
 
[18-69] 
 
[18-59] 
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Current admission (days) 57.61 (78.25) 64.57 (93.88) 46.06 (39) 
  [range] 
 
[1-554] 
 
[1-554] 
 
[1-146] 
 
 Previous admissions 1.59 (2.69) 1.64 (2.65) 1.51 (2.78) 
  [range] 
 
[0-15] 
 
[0-12] 
 
[0-15] 
 
 Subsequent admissions 2.21 (2.84) 2.59 (3.05) 1.58 (2.34) 
  [range] 
 
[0-14] 
 
[0-14] 
 
[0-9] 
 
 Subsequent LOS (days) 
[range] 
 
218.48 (348.55) 
[0-1572] 
 
269.98 (393.44) 
[0-1572] 
 
132.98 (236.99) 
[0-1130] 
 
 
     LOS, length of stay (number of subsequent inpatient days);  
a. Using one or more substances other than cannabis 
   
 
 
Table 2. Effect of cannabis use on inpatient hospital readmissions over the following 6 years 
       A 
      
         B SE Wald Chi-Square p value 
  Cannabis use 0.558 0.256 4.744 0.029 
  Age 0.002 0.012 0.037 0.848 
  Gender (Male) -0.012 0.263 0.002 0.963 
  Ethnicity (Asian) -0.028 0.428 0.004 0.948 
  Ethnicity (Black) 0.845 0.275 9.434 0.002 
  Ethnicity (Mixed) 0.577 0.446 1.671 0.196 
  Current admission 0.001 0.002 0.001 0.982 
  Previous admissions 0.150 0.044 11.622 < 0.001 
  
       N = 133; Likelihood Ratio Chi square = 34.03, p < 0.001, df = 8 
   
       B 
      
         B SE Wald Chi-Square p value 
  Cannabis use 1.177 0.655 3.227 0.072 
  Age 0.010 0.016 0.378 0.539 
  Gender (male) -0.181 0.359 0.253 0.615 
  Ethnicity (Asian) -0.492 0.566 0.754 0.385 
  Ethnicity (Black) 0.766 0.415 3.408 0.065 
  Ethnicity (Mixed) 0.991 0.599 2.733 0.098 
  Alcohol use -0.391 0.451 0.754 0.385 
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Tobacco use -0.626 0.719 0.757 0.384 
  Stimulant use 0.366 0.484 0.572 0.450 
  Current admission -0.001 0.003 0.076 0.783 
  Previous admissions 0.166 0.084 3.942 0.047 
  
       N = 71; Likelihood Ratio Chi square = 25.29, p = 0.008, df = 11 
    
A refers to the effect of cannabis use on hospital readmissions over the following 6 years, controlling 
for baseline clinical characteristics; B refers to the effect of cannabis use on hospital readmissions 
over the following 6 years, controlling for baseline clinical characteristics as well as other substances 
use such as tobacco, alcohol and stimulants. 
 
 
 
Table 3. Effect of cannabis use on inpatient length of stay (LOS) over the following 6 years 
       A 
      
         B SE Wald Chi-Square p value 
  Cannabis use 0.767 0.231 10.967 0.001 
  Age -0.019 0.009 4.182 0.041 
  Gender (male) 0.049 0.250 0.038 0.844 
  Ethnicity (Asian) 0.034 0.322 0.011 0.917 
  Ethnicity (Black) 0.718 0.207 12.010 0.001 
  Ethnicity (Mixed) 0.549 0.346 2.521 0.112 
  Current admission 0.002 0.001 1.382 0.240 
  Previous admissions 0.177 0.050 12.378 < 0.001 
  
       N = 133; Likelihood Ratio Chi square = 46.53, p < 0.001, df = 8 
   
       B 
      
         B SE Wald Chi-Square p value 
  Cannabis use 1.412 0.702 4.045 0.044 
  Age -0.013 0.014 0.867 0.352 
  Gender (male) -0.163 0.382 0.183 0.668 
  Ethnicity (Asian) 0.448 0.459 0.951 0.330 
  Ethnicity (Black) 1.745 0.349 25.031 < 0.001 
  Ethnicity (Mixed) 2.030 0.547 13.762 < 0.001 
  Alcohol use -1.415 0.392 13.006 < 0.001 
  Tobacco use -0.684 0.658 1.081 0.299 
  Stimulant use 1.050 0.445 5.578 0.018 
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Current admission 0.005 0.003 2.976 0.084 
  Previous admissions 0.331 0.089 13.712 < 0.001 
  
       N = 71; Likelihood Ratio Chi square = 73.68, p < 0.001, df = 11 
    
A refers to the effect of cannabis use on inpatient length of stay (LOS) over the following 6 years, 
controlling for baseline clinical characteristics; B refers to the effect of cannabis use on inpatient 
length of stay (LOS) over the following 6 years, controlling for baseline clinical characteristics as well 
as other substances use such as tobacco, alcohol and stimulants. 
 
 
 
 
Table 4. Interaction between cannabis use and gender on inpatient length of stay  
(LOS) over the following 6 years 
    
        B SE Wald Chi-Square p value 
 Male Cannabis users 1.494 0.722 4.284 0.038 
 Male Cannabis-naïve  -0.640 0.426 2.257 0.133 
 Female Cannabis users 0.734 0.776 0.894 0.344 
 Age -0.014 0.014 1.038 0.308 
 Ethnicity (Asian) 0.662 0.501 1.750 0.186 
 Ethnicity (Black) 1.989 0.368 29.237 < 0.001 
 Ethnicity (Mixed) 2.149 0.539 15.889 < 0.001 
 Alcohol use -1.487 0.374 15.847 < 0.001 
 Tobacco use -0.640 0.667 0.921 0.337 
 Stimulant use 0.601 0.517 1.352 0.245 
 Current admission 0.006 0.003 3.649 0.056 
 Previous admissions 0.341 0.096 12.653 < 0.001 
  
    
 N = 71; Likelihood Ratio Chi square = 78.59, p < 0.001, df = 12 
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Table 5. Interaction between cannabis use and ethnicity on inpatient hospital  
 readmissions and length of stay (LOS) over the following 6 years 
  
      A. Inpatient hospital readmissions 
    
        B SE Wald Chi-Square p value 
 Asian Cannabis users 0.225 0.969 0.054 0.817 
 Asian Cannabis-naïve  -1.321 0.961 1.889 0.169 
 Black Cannabis users 1.545 0.787 3.859 0.049 
 Black Cannabis -naïve  0.046 0.597 0.006 0.939 
 Mixed Cannabis users 1.632 1.099 2.205 0.138 
 Mixed Cannabis-naïve 0.407 0.861 0.224 0.636 
 White Cannabis users 0.118 0.920 0.017 0.898 
 Age 0.018 0.018 0.999 0.318 
 Gender (Male) -0.170 0.363 0.220 0.639 
 Alcohol use -0.372 0.448 0.689 0.407 
 Tobacco use -0.654 0.739 0.783 0.376 
 Stimulant use 0.409 0.520 0.617 0.432 
 Current admission -0.001 0.003 0.040 0.842 
 Previous admissions 0.174 0.086 4.130 0.042 
 
      N = 71; Likelihood Ratio Chi square = 28.27, p = 0.013, df = 14 
  
      B. Length of stay (LOS) 
     
        B SE Wald Chi-Square p value 
 Asian Cannabis users 1.084 1.029 1.111 0.292 
 Asian Cannabis-naïve  -0.680 0.584 1.355 0.244 
 Black Cannabis users 2.392 0.898 7.103 0.008 
 Black Cannabis -naïve  0.735 0.500 2.162 0.141 
 Mixed Cannabis users 2.630 1.076 5.976 0.015 
 Mixed Cannabis-naïve 0.922 0.866 1.132 0.287 
 White Cannabis users -0.633 1.004 0.397 0.529 
 Age 0.004 0.016 0.068 0.794 
 Gender (Male) 0.172 0.393 0.191 0.662 
 Alcohol use -1.456 0.381 14.603 < 0.001 
 Tobacco use -0.318 0.825 0.149 0.700 
 Stimulant use 0.775 0.515 2.264 0.132 
 Current admission 0.007 0.003 3.845 0.050 
 Previous admissions 0.308 0.093 10.830 0.001 
 
      N = 71; Likelihood Ratio Chi square = 86.76, p < 0.001, df = 14 
   
 
